Business
Myriad Genetics Announces Multiple Presentations at the 2019 American College of Rheumatology Annual Meeting
SALT LAKE CITY, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today
About this update from Myriad Genetics, Inc.
[{"type":"text","content":"SALT LAKE CITY, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced that three studies on Vectra® will be featured at the 2019 American College of Rheumatology (ACR) Annual Meeting being held Nov. 8-13, 2019 in Atlanta, GA.\n \"We are excited to share important new data that demonstrates how precision medicine can advance care for people with rheumatoid arthritis (RA),\" said Elena Hitraya, M.D., Ph.D., rheumatologist and chief medical officer at Myriad Autoimmune. \"Our studies show that Vectra, an objective measure of RA inflammation, helps identify people with RA that are at risk of joint damage and cardiovascular risk.” A list of presentations at 2019 ACR is below. Please visit Myriad Autoimmune at booth #1419 to learn more about Vectra. Follow Myriad on Twitter via @myriadgenetics and follow meeting news by using the hashtag #ACR19. Featured Research at 2019 ACRMyriad Product Abstract Author Poster Details Vectra® Predicting Risk of Radiographic Progression for Patients with Rheumatoid Arthritis Jeffrey CurtisPoster #466Sunday, Nov. 10, 20199:00-11:00 a.m.Leptin-Adjustment of the Multi-Biomarker Disease Activity (MBDA) Score Reduces the Influence of Adiposity Joshua BakerPoster #1357Monday, Nov. 11, 20199:00-11:00 a.m.Derivation and Validation of a Biomarker-Based Cardiovascular Risk Prediction Score in Rheumatoid Arthritis Jeffrey CurtisPoster #2350Tuesday, Nov. 12, 20199:00-11:00 a.m. About Vectra®Vectra is a multi-biomarker molecular blood test that provides an objective and personalized measure of inflammatory disease activity in patients with rheumatoid arthritis. Vectra provides unsurpassed ability to predict radiographic progression and can help guide medical management decisions with the goal of improving patient outcomes. Vectra testing is performed at a state-of-the-art CLIA (Clinical Laboratory Improvement Amendments) facility. Test results are reported to the physician five to seven days from shipping of the specimen. Physicians can receive test results by fax or the private web portal, VectraView. For more information on Vectra, please visit: www.vectrascore.com. About Myriad GeneticsMyriad Genetics Inc. is a leading precision medicine company dedicated to being a trusted advisor transforming patient lives worldwide wi...